MedTrace Logo

Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease

NCT01693081 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2012-09-26

No results posted yet for this study

Summary

'Off periods' where people with Parkinson's disease are slow, stiff and unable to function are disabling, and a treatment which can converts people to a "on", good, able to function state would be extremely useful. We assessed safety, tolerability and efficacy of inhaled dry powder apomorphine (VR040) in a clinic-based study in this setting.

Conditions

Interventions

DRUG

VR040/Aspirair® inhaler

Dry Powder inhaled apomorphine

DRUG

placebo

Sponsors & Collaborators

  • Vectura Limited

    collaborator INDUSTRY

  • South Glasgow University Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Donald Grosset, MD · South Glasgow NHS Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-07-31
Completion
2009-07-31

Countries

  • Serbia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01693081 on ClinicalTrials.gov